| Date | Title | Description |
| 12.01.2022 | Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update | ~ Reports KEVEYIS® (dichlorphenamide) Second Quarter 2021 Revenue of $10.0 Million, a 28 Percent Increase Compared to $7.8 Million of Revenue During Second Quarter of 2020 ~
~ Strongbridge Remains On-Track to Meet, or Potentially Exceed, t... |
| 17.07.2017 | Strongbridge Biopharma Secures $53 Million Financing From CRG | Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it has entered... |
| 30.12.2016 | Strongbridge Biopharma Closes $35M Equity Financing and $40 Million Credit Facility | DUBLIN, Ireland and TREVOSE, Pa., Dec. 29, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseas... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 22.10.2015 | Insiders help Strongbridge limp to a downsized $25M IPO | Strongbridge Biopharma ($SBBP) has struggled through choppy conditions to complete a $25 million (€22 million) listing on Nasdaq. The rare disease player pulled off the dramatically downsized IPO by relying heavily on the support of existin... |
| - | A diagnostic odyssey: spotting the zebras among the horses | By Michele Cunningham
While individually rare, collectively there are more than 7,000 rare diseases that affect nearly 30 million people in the U.S.[i] Their symptoms and disabilities may vary, but the stories they tell, share many commonal... |
| - | Strongbridge Biopharma plc Secures $53 Million Financing From CRG | ~ Financing Comprised of $50 Million Credit Facility and $3 Million Equity Investment ~
~ Simultaneously Retiring Existing Debt ~
~ Funds Received at Close Provide Sufficient Cash Under Current Operating Plan to Extend Cash Runway to Posi... |
| - | Strongbridge Biopharma plc Announces Presentation at Biotech Showcase 2016 | DUBLIN, Ireland and TREVOSE, Pa., Dec. 16, 2015 (GLOBE NEWSWIRE) –Strongbridge Biopharma plc (NASDAQ:SBBP) today announced that management will be presenting at Biotech Showcase 2016 to be held January 11 – 13, 2016 in San Francisco.
Matth... |
| - | Strongbridge Biopharma plc Provides Corporate Update and Reports First Quarter 2017 Financial Results | Strongbridge Commercial Introduction of KEVEYIS® (dichlorphenamide) in Mid-April Shows Encouraging Initial Demand ~
~ RECORLEV™ (levoketoconazole) SONICS Study Remains on Track to Complete Enrollment in the Second Quarter of 2017; Data Saf... |
| - | Strongbridge Biopharma plc Reports Second Quarter 2019 Financial Results and Provides Corporate Update | ~ KEVEYIS®(dichlorphenamide) Second Quarter 2019 Revenue of $6.1 Million ~
~ Company on Track to Meet Full-Year 2019 KEVEYIS® Revenue Guidance of $18 to $20 Million ~
~ Enrollment in Phase 3 LOGICS Study for RECORLEV™ (levoketoconazole) P... |
| - | Strongbridge Biopharma plc Announces Appointment of Matthew Pauls to its Board of Directors | September 4, 2015 – Dublin, Ireland and Trevose, Pa., USA – Strongbridge Biopharma plc, formerly known as Cortendo plc, (the “Company”), announced today that Matthew Pauls, president and chief executive officer of Strongbridge Biopharma plc... |
| - | Strongbridge Biopharma plc Announces $35 Million Equity Financing | DUBLIN, Ireland and TREVOSE, Pa., Dec. 23, 2016 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare disease... |
| - | Strongbridge Biopharma plc to Present at the Canaccord Genuity 37th Annual Growth Conference | DUBLIN, Ireland and TREVOSE, Pa., Aug. 10, 2017 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases... |
| - | Strongbridge Biopharma plc to Participate in the Canaccord Genuity Rare Disease and BioPharma One-on-One Day | DUBLIN, Ireland and TREVOSE, Pa., Feb. 02, 2017 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare disease... |
| - | Strongbridge Biopharma plc Announces Appointment of Garheng Kong, M.D., Ph.D., MBA, to its Board of Directors | September 15, 2015 – Dublin, Ireland and Trevose, Pa., USA – Strongbridge Biopharma plc announced today that Garheng Kong, M.D., Ph.D., MBA, founder and managing partner of HealthQuest Capital, has been appointed to the Company’s Board of D... |
| - | Cortendo plc Changes Name to Strongbridge Biopharma plc | Dublin, Ireland and Trevose, Pa., USA – September 4, 2015 – Cortendo plc announced today that the Company has changed its name to Strongbridge Biopharma plc.
Strongbridge Biopharma will become effective immediately and the new logo and cor... |
| - | Strongbridge Biopharma plc Provides Corporate Update and Reports Third Quarter 2017 Financial Results | ~ Achieved Net Product Sales of $2.5 Million for KEVEYIS®(dichlorphenamide), a 67% Revenue Growth Increase over the Previous Quarter ~
~ Increasing Commercial Investment in KEVEYIS with Expansion of Sales Force and
Launch of Genetic Testi... |
| - | Strongbridge Biopharma plc Announces Presentation at 15th Annual Needham Healthcare Conference | DUBLIN, Ireland and TREVOSE, Pa., April 06, 2016 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc (NASDAQ:SBBP), a global rare disease biopharmaceutical company focused on the development and commercialization of novel therapeutic options, tod... |
| - | Strongbridge Biopharma plc Announces Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushi... | ~ LOGICS Study Met Primary Endpoint with High Statistical Significance; Results at the End of the Randomized-Withdrawal Phase of the Study Demonstrated that Withdrawing Patients to Placebo Resulted in a Loss of Cortisol Response in 54.5 Per... |
| - | Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s Syndrome | Notice of Allowance to Lead to Second Method of Use Patent for RECORLEV ~DUBLIN, Ireland and TREVOSE, Pa., Jan. 18, 2018 (GLOBE NEWSWIRE) —
Strongbridge Biopharma plc (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focus... |
| - | Strongbridge Biopharma plc Reports Second Quarter 2018 Financial Results and Provides Corporate Update | ~ Statistically Significant Positive Top-line Clinical Results Reported from SONICS Phase 3 Study of RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome ~
~ Rare Endocrine Franchise Expands with the U.S. Launch of MACRILEN™ (maci... |
| - | Strongbridge Biopharma plc Added to the NASDAQ Biotech Index | DUBLIN, Ireland and TREVOSE, Pa., Dec. 13, 2017 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare disease... |
| - | Strongbridge Biopharma plc to Present KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis Data at the 2018 American Academy of Neurology Annual Meeting | ~ Post-Hoc Analysis of Phase 3 Placebo-Controlled Study of KEVEYIS Showed Adolescents had Similar Improvements in Short-Term Attack Rates as Adults ~
~ Pooled Analysis of Two Phase 3 Studies Further Demonstrate the Clinical Benefit and Use... |
| - | Strongbridge Biopharma plc Announces Positive Top-Line Results from the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome | ~ SONICS Study Met Primary Endpoint with RECORLEV Demonstrating a Statistically Significant Normalization Rate of Urinary Free Cortisol at Six Months ~
~ Key Secondary Endpoints Evaluating Cardiovascular Risk Markers Showed Statistically S... |
